Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Knight Cancer Institute, |
RCV000721113 | SCV000845774 | likely pathogenic | Atypical chronic myeloid leukemia, BCR-ABL1 negative | 2018-09-25 | no assertion criteria provided | clinical testing | Primary patient samples are sensitive to kinase inhibitors (quizartinib and sorafenib) |